Drug Profile
Research programme: parainfluenza virus vaccines - AstraZeneca
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parainfluenza virus infections
Most Recent Events
- 26 Jul 2007 Preclinical trials in Parainfluenza virus infections in USA (unspecified route)